Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
MindMed Initiates Phase 2a LSD Trial for the Treatment of Adult ADHD
The company announced the initiation of Phase 2a proof-of-concept (POC) trial of lysergic acid diethylamide (LSD) in adult patients with attention deficit hyperactivity disorder (ADHD). The first site has been activated and patient enrollment is expected to start imminently. The POC trial will be conducted in collaboration with the University Hospital Basel in Switzerland and Maastricht University in the Netherlands and is designed to evaluate the therapeutic utility of repeated low doses of LSD.
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics
atai Impact’s first major initiative will support promising academics in researching the therapeutic potential of psychedelic compounds to address unmet needs in mental health. The Fund aims to help unlock the mysteries of the brain, improve the treatment of mental health conditions and positively change the future of brain health through psychedelic research
Nova Mentis and Mycrodose Therapeutics Announce Major Milestone with Transdermal Technology for Fragile X Syndrome Clinical
“This cooperative transdermal delivery technology expands the possibilities of treating chronic developmental disorders such as Fragile X Syndrome without exposing the child or adult to intolerable hallucinogenic side effects,” – Will Rascan, NOVA’s CEO & President.
Psyched Wellness Announces Path to Market for AME-1-derived Products in the USA
The company announced that it is moving forward with its regulatory strategy to launch its Amanita Muscaria extract (“AME-1”)-derived consumer products in-stores in the United States market in the second quarter of 2022.
Entheon Biomedical Announces EEG Patent Application & Provides Research Update
“Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. “With the filing of our provisional patent application, Entheon is building an IP foundation to better facilitate safe and precise use of psychedelics to deliver improved patient outcomes.”
atai Life Sciences Added to NASDAQ Biotechnology Index
The company announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective as of market open on Monday, December 20, 2021. The NBI is a stock market index made up of securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria.
PharmaTher Announces Positive Research Results for LSD Microneedle Patch
The company announced that it has successfully completed its first research study evaluating MicroDose-MN™, a proprietary microneedle (“MN”) patch for the intradermal delivery of psychedelics, in delivering lysergic acid diethylamide (“LSD”). These results provide support to file for an IND application with the FDA to conduct Phase 2 clinical studies in 2022 with LSD for various indications.
